logo
What is 'Red 40,' food dye banned by FDA and RFK Jr?

What is 'Red 40,' food dye banned by FDA and RFK Jr?

Express Tribune23-04-2025

The U.S. Food and Drug Administration (FDA) has banned Red Dye No. 40 in food and drinks, citing growing evidence that the artificial colouring may contribute to hyperactivity and behavioural issues in children.
Red Dye 40, also known as Allura Red, has been a staple in children's snacks for decades, brightening cereals, candies, and drinks with vivid red hues. But amid increasing scrutiny, the FDA has now prohibited its use, triggering a major shift in the food industry.
The agency said its decision followed new research showing potential links between the dye and neurobehavioral changes in children, including hyperactivity, impulsiveness, and attention issues.
A 2022 meta-analysis reviewing 25 studies found consistent behavioural effects in some children following consumption of Red 40.
Although not all children are affected, the FDA concluded the risks outweigh the benefits of using the dye. Officials also noted allergic and inflammatory responses in animal studies, strengthening the case for a ban.
European regulators had long required warning labels on products containing Red 40. The FDA's new ban goes further, removing the ingredient entirely from the U.S. market.
Products impacted include cereals like Froot Loops, candies such as Skittles, and beverages including fruit punches and sports drinks. Red 40 has also been used in baked goods, flavoured snacks, condiments, and even some vitamin drinks.
Manufacturers are already preparing to reformulate products using natural colourants. These include plant-based alternatives such as beet juice, carrot extract, spirulina, and paprika.
Companies like Kellogg's and Mars, Inc. are among those exploring natural replacements.
Food scientists say natural colourings may produce subtler shades than artificial dyes, but they expect minimal impact on flavour or texture.
The move has been widely praised by parents and paediatricians. Many parents who had already removed Red 40 from their children's diets reported noticeable improvements in behaviour, sleep, and focus.
The American Academy of Pediatrics welcomed the FDA's action, calling it a win for child health. Still, experts advise parents to consider other factors such as sugar and sleep that can also affect behaviour.
The FDA's decision marks a shift in public health policy, acknowledging consumer concerns and scientific findings. While foods may look a little less vibrant, many families see the change as a positive step towards safer nutrition for children.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Collaborative efforts required to reduce smoking rates faster
Collaborative efforts required to reduce smoking rates faster

Business Recorder

time03-06-2025

  • Business Recorder

Collaborative efforts required to reduce smoking rates faster

Pakistan stands at a critical juncture in its efforts to reduce smoking. Rapid progress will require a united front—governments, businesses, health organisations, and individuals working in close collaboration. Without strong leadership and sustained public — private partnerships, the vision of a smoke-free future will remain out of reach. Governments must recognise the important role of smoke-free products in reducing tobacco-related harm. Embracing science and innovation, along with clear regulations that prevent youth uptake, enables them to make informed adult choices. Addressing misinformation and fostering dialogue between public and private stakeholders is equally crucial. A powerful example of this approach can be seen in Sweden. By embracing smoke-free alternatives alongside conventional tobacco control efforts, Sweden has rapidly reduced its smoking rates and is now poised to become Europe's first smoke-free country, with fewer than 5% of adults smoking. This forward-thinking model has led Sweden to achieve one of the lowest smoking rates in the developed world. Karl Fagerström, a clinical psychologist from Spain, further endorsed the Swedish philosophy, stating: 'Public health benefits of the Swedish strategy are 'very high.' Compared to the rest of the European Union, Sweden has 44% fewer tobacco-related deaths. Data shows that, although Sweden has a level of nicotine consumption similar to the European average, the country has a 41% lower incidence of lung cancer.' Pakistan can draw lessons from Sweden's success. Encouraging the use of scientifically backed smoke-free products has the potential to offer a less harmful path for adult smokers and reduce the long-term health burden on the country's healthcare system. Abu Bakar Kareem (Karachi) Copyright Business Recorder, 2025

Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio

Express Tribune

time02-06-2025

  • Express Tribune

Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio

In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.

US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older

Business Recorder

time31-05-2025

  • Business Recorder

US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store